217 related articles for article (PubMed ID: 18371053)
1. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber.
Günther C; Laske J; Frind A; Julius U; Pfeiffer C
J Dtsch Dermatol Ges; 2008 Aug; 6(8):661-3. PubMed ID: 18371053
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome.
Frost N; Messer G; Fierlbeck G; Risler T; Lytton SD
Ann N Y Acad Sci; 2005 Jun; 1051():591-6. PubMed ID: 16126999
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
4. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris.
Dietze J; Hohenstein B; Tselmin S; Julius U; Bornstein SR; Beissert S; Günther C
Atheroscler Suppl; 2017 Nov; 30():271-277. PubMed ID: 29096849
[TBL] [Abstract][Full Text] [Related]
5. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
[TBL] [Abstract][Full Text] [Related]
7. Immunoadsorption in pemphigus.
Eming R; Hertl M
Autoimmunity; 2006 Nov; 39(7):609-16. PubMed ID: 17101505
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
9. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid.
Mazzi G; Raineri A; Zanolli FA; Da Ponte C; De Roia D; Santarossa L; Guerra R; Orazi BM
Transfus Apher Sci; 2003 Feb; 28(1):13-8. PubMed ID: 12620264
[TBL] [Abstract][Full Text] [Related]
10. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
Turner MS; Sutton D; Sauder DN
J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
13. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
Aoyama Y; Nagasawa C; Nagai M; Kitajima Y
Eur J Dermatol; 2008; 18(5):557-60. PubMed ID: 18693160
[TBL] [Abstract][Full Text] [Related]
14. Life-threatening bullous dermatoses: Pemphigus vulgaris.
Ruocco E; Baroni A; Wolf R; Ruocco V
Clin Dermatol; 2005; 23(3):223-6. PubMed ID: 15896536
[TBL] [Abstract][Full Text] [Related]
15. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
16. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
Lüftl M; Stauber A; Mainka A; Klingel R; Schuler G; Hertl M
Br J Dermatol; 2003 Sep; 149(3):598-605. PubMed ID: 14510995
[TBL] [Abstract][Full Text] [Related]
17. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
18. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris.
Euler HH; Löffler H; Christophers E
Arch Dermatol; 1987 Sep; 123(9):1205-10. PubMed ID: 3632005
[TBL] [Abstract][Full Text] [Related]
19. Current therapy of the pemphigus group.
Kasperkiewicz M; Schmidt E; Zillikens D
Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
[TBL] [Abstract][Full Text] [Related]
20. Immunoadsorption in the treatment of pemphigus.
Mlynek A; Meurer M
Atheroscler Suppl; 2009 Dec; 10(5):107-9. PubMed ID: 20129386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
